Impact of Telemonitoring on Multiple Myeloma Patients
Practical Solutions and Value
Multiple myeloma (MM) is a serious condition with significant impact on patients’ lives. To address the challenges of complex treatment regimens, the MM e-coach telemonitoring tool was developed and tested. This study aims to assess the impact of telemonitoring on medication adherence, complications, and quality of life in MM patients.
During the study, 150 recently diagnosed MM patients will be recruited to compare the telemonitoring (MM e-coach) with standard MM care. The primary outcome will be adherence to treatment, with secondary outcomes including patient-reported measures, adverse events, and overall survival. Online measurements will be taken at various time points over 12 months.
The study has received ethics approval and the results will be shared with healthcare communities through peer-reviewed journals and conferences. The study is registered under ClinicalTrials.gov number: NCT05964270 and ABR number: NL75771.075.20.
Clinical trials play a crucial role in developing effective treatments, and our AI-driven platform, DocSym, consolidates clinical knowledge and protocols for easy access by clinicians. Additionally, our mobile apps support scheduling, treatment monitoring, and telemedicine, helping to streamline operations and improve patient care.
AI technology can enhance clinic workflows and patient outcomes, reducing paper-based routines. Learn more about our solutions at aidevmd.com.
